Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/30741
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartínez-Ortega, Leticia-
dc.contributor.authorMIRA CARRIÓ, AMALIA-
dc.contributor.authorFernandez-Carvajal, Asia-
dc.contributor.authorMateo , C. Reyes-
dc.contributor.authorMallavia, Ricardo-
dc.contributor.authorFalcó, Alberto-
dc.contributor.otherDepartamentos de la UMH::Agroquímica y Medio Ambientees_ES
dc.date.accessioned2024-01-26T10:49:20Z-
dc.date.available2024-01-26T10:49:20Z-
dc.date.created2018-12-23-
dc.identifier.citationPharmaceutics 2019, 11, 14es_ES
dc.identifier.issn1999-4923-
dc.identifier.urihttps://hdl.handle.net/11000/30741-
dc.description.abstractPsoriasis is a chronic autoimmune systemic disease with an approximate incidence of 2% worldwide; it is commonly characterized by squamous lesions on the skin that present the typical pain, stinging, and bleeding associated with an inflammatory response. In this work, poly(methyl vinyl ether-alt-maleic ethyl monoester) (PMVEMA-ES) nanofibers have been designed as a delivery vehicle for three therapeutic agents with palliative properties for the symptoms of this disease (salicylic acid, methyl salicylate, and capsaicin). For such a task, the production of these nanofibers by means of the electrospinning technique has been optimized. Their morphology and size have been characterized by optical microscopy and scanning electron microscopy (SEM). By selecting the optimal conditions to achieve the smallest and most uniform nanofibers, approximate diameters of up to 800–900 nm were obtained. It was also determined that the therapeutic agents that were used were encapsulated with high efficiency. The analysis of their stability over time by GC-MS showed no significant losses of the encapsulated compounds 15 days after their preparation, except in the case of methyl salicylate. Likewise, it was demonstrated that the therapeutic compounds that were encapsulated conserved, and even improved, their capacity to activate the transient receptor potential cation channel 1 (TRPV1) channel, which has been associated with the formation of psoriatic lesions.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent14es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPMVE/MAes_ES
dc.subjectelectrospinninges_ES
dc.subjectnanofiberses_ES
dc.subjectcapsaicines_ES
dc.subjectpsoriasises_ES
dc.subjectTRPV1es_ES
dc.subject.classificationQuímica Físicaes_ES
dc.subject.otherCDU::5 - Ciencias puras y naturales::54 - Químicaes_ES
dc.titleDevelopment of A New Delivery System Based on Drug-Loadable Electrospun Nanofibers for Psoriasis Treatmentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics11010014es_ES
Appears in Collections:
Artículos Agroquímica y Medio Ambiente


Thumbnail

View/Open:
 pharmaceutics-11-00014.pdf

2,06 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???